Roivant's pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. Roivant Sciences has drawn fresh attention after announcing a US$2.25b global settlement with Moderna that ends ongoing patent litigation, along with positive IMVT-1402 rheumatoid arthritis data and Breakthrough Therapy Designation for brepocitinib.
Cyborg Score Rationale
Roivant's net loss narrowed 45% to US$299.8m in FY 2026, demonstrating progress toward profitability alongside advancing late-stage and mid-stage drug programs. The company ended the quarter with $4.5 billion in cash, supporting continued R&D investment. Key clinical catalysts remain ahead in 2026–2027.
Top Insights
Genevant (Roivant subsidiary) and Arbutus secured a $2.25 billion global settlement with Moderna in March 2026, with $950 million upfront expected in July 2026.
Roivant reported encouraging preliminary open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis and is advancing a Phase II study of inhaled mosliciguat, with top-line data planned for H2 2026.
Brepocitinib is positioned as a potential first-in-class therapy in several orphan autoimmune diseases, targeting large unmet needs and commercial opportunities.
Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.
Named Competitors
Rinvoq — JAK inhibitor for autoimmune diseases
Veltassa — Autoimmune and specialty therapeutics
Imraldi — FcRn-targeted biologics for autoimmune conditions
Recent Developments
(May 2026) Reported fourth-quarter sales of US$2.52 million with net income of US$302.99 million, alongside a full-year net loss of US$299.77 million on US$8.26 million in sales.
(March 2026) Announced $2.25 billion global settlement with Moderna to resolve patent litigation involving Genevant's LNP delivery technology.
(Early 2026) Planned Brepocitinib NDA filing in dermatomyositis in early calendar 2026 with ongoing commercial preparation.
Open the full interactive Roivant Sciences Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.